338 related articles for article (PubMed ID: 27006892)
1. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma.
Sato N; Cheng XB; Kohi S; Koga A; Hirata K
Acta Pharm Sin B; 2016 Mar; 6(2):101-5. PubMed ID: 27006892
[TBL] [Abstract][Full Text] [Related]
2. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight.
Sato N; Kohi S; Hirata K; Goggins M
Cancer Sci; 2016 May; 107(5):569-75. PubMed ID: 26918382
[TBL] [Abstract][Full Text] [Related]
3. The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma.
Kudo D; Suto A; Hakamada K
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282922
[TBL] [Abstract][Full Text] [Related]
4. 4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions.
Cheng XB; Sato N; Kohi S; Koga A; Hirata K
Oncol Lett; 2018 May; 15(5):6297-6301. PubMed ID: 29725394
[TBL] [Abstract][Full Text] [Related]
5. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives.
Wu Y; Zhang C; Jiang K; Werner J; Bazhin AV; D'Haese JG
Front Oncol; 2020; 10():621937. PubMed ID: 33520728
[TBL] [Abstract][Full Text] [Related]
6. Increase of Tumor Infiltrating γδ T-cells in Pancreatic Ductal Adenocarcinoma Through Remodeling of the Extracellular Matrix by a Hyaluronan Synthesis Suppressor, 4-Methylumbelliferone.
Suto A; Kudo D; Yoshida E; Nagase H; Suto S; Mimura J; Itoh K; Hakamada K
Pancreas; 2019 Feb; 48(2):292-298. PubMed ID: 30589828
[TBL] [Abstract][Full Text] [Related]
7. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential.
Cannon A; Thompson C; Hall BR; Jain M; Kumar S; Batra SK
Genes Cancer; 2018 Mar; 9(3-4):78-86. PubMed ID: 30108679
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer.
Koltai T; Reshkin SJ; Carvalho TMA; Cardone RA
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921242
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma.
Kudo Y; Kohi S; Hirata K; Goggins M; Sato N
Oncotarget; 2019 Sep; 10(54):5592-5604. PubMed ID: 31608136
[No Abstract] [Full Text] [Related]
11. Hyaluronidase-Expressing
Ebelt ND; Zuniga E; Passi KB; Sobocinski LJ; Manuel ER
Mol Cancer Ther; 2020 Feb; 19(2):706-716. PubMed ID: 31694889
[TBL] [Abstract][Full Text] [Related]
12. Tumor Stroma as a Therapeutic Target for Pancreatic Ductal Adenocarcinoma.
Lee DU; Han BS; Jung KH; Hong SS
Biomol Ther (Seoul); 2024 May; 32(3):281-290. PubMed ID: 38590092
[TBL] [Abstract][Full Text] [Related]
13. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
Jiang B; Zhou L; Lu J; Wang Y; Liu C; You L; Guo J
Front Oncol; 2020; 10():576399. PubMed ID: 33178608
[TBL] [Abstract][Full Text] [Related]
14. Biomaterial substrate-derived compact cellular spheroids mimicking the behavior of pancreatic cancer and microenvironment.
Wong CW; Han HW; Tien YW; Hsu SH
Biomaterials; 2019 Aug; 213():119202. PubMed ID: 31132644
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.
Blair AB; Kim VM; Muth ST; Saung MT; Lokker N; Blouw B; Armstrong TD; Jaffee EM; Tsujikawa T; Coussens LM; He J; Burkhart RA; Wolfgang CL; Zheng L
Clin Cancer Res; 2019 Sep; 25(17):5351-5363. PubMed ID: 31186314
[TBL] [Abstract][Full Text] [Related]
16. Advances in Pancreatic Ductal Adenocarcinoma Treatment.
Anderson EM; Thomassian S; Gong J; Hendifar A; Osipov A
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771675
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer: Stroma and its current and emerging targeted therapies.
Kota J; Hancock J; Kwon J; Korc M
Cancer Lett; 2017 Apr; 391():38-49. PubMed ID: 28093284
[TBL] [Abstract][Full Text] [Related]
18. Targeting Pancreatic Stellate Cells in Cancer.
Schnittert J; Bansal R; Prakash J
Trends Cancer; 2019 Feb; 5(2):128-142. PubMed ID: 30755305
[TBL] [Abstract][Full Text] [Related]
19. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors.
Manuel ER; Chen J; D'Apuzzo M; Lampa MG; Kaltcheva TI; Thompson CB; Ludwig T; Chung V; Diamond DJ
Cancer Immunol Res; 2015 Sep; 3(9):1096-107. PubMed ID: 26134178
[TBL] [Abstract][Full Text] [Related]
20. Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches.
Carvalho TMA; Di Molfetta D; Greco MR; Koltai T; Alfarouk KO; Reshkin SJ; Cardone RA
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
